Company Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Jul 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Diana M. Brainard M.D. |
Contact Details
Address: 1100 Winter Street Waltham, Massachusetts United States | |
| Website | https://www.allovir.com |
Stock Details
| Ticker Symbol | ALVR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 019818103 |
| ISIN Number | US0198181036 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Diana M. Brainard M.D. | Chief Executive Officer & Director |
| Vikas Sinha C.A., CPA, M.B.A. | President, Chief Financial Officer & Director |
| Brett R. Hagen | Chief Accounting Officer |
| Cintia Piccina Pharm.D. | Chief Commercial Officer |
| David L. Hallal | Executive Chairman of the Board |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer |
| Edward Miller J.D. | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 4 | Filing |
| Jan 13, 2025 | 4 | Filing |
| Jan 13, 2025 | 4 | Filing |
| Jan 10, 2025 | 425 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 425 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 425 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 11, 2024 | 4 | Filing |